NCT00480662已完成3 期
A 6-Month, Multicenter, Double-Blind, Randomized, Active-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Alendronate 280-mg Oral Buffered Solution Once Weekly in Patients With Paget's Disease of Bone
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 60
- 主要终点
- Patients will have a decrease of at least 30% in their blood alkaline phosphatase level after 6 months
研究概览
简要总结
To test the safety, effectiveness of MK0217 when taken once a week for six months in treating patients with Paget's bone disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 90 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female, ages 18 to 90 years with a diagnosis of Paget's bone disease
排除标准
- •Patient cannot stand or sit upright for at least 30 minutes
- •Patient has difficulty swallowing or problems with digestive system
结局指标
主要结局
Patients will have a decrease of at least 30% in their blood alkaline phosphatase level after 6 months
次要结局
- MK0217 will be safely tolerated
研究者
相似试验
已完成
3 期
A Research Study to Evaluate the Safety and Effectiveness of MK0217 to Prevent and Treat Bone Loss (0217-193)(COMPLETED)OsteoporosisNCT00480766Organon and Co173
已完成
2 期
A Study to Assess the Safety and Efficacy of an Investigational Drug (MK-686) in Patients With Osteoarthritis (0686-006)OsteoarthritisNCT00296569Merck Sharp & Dohme LLC150
终止
2 期
Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)Alzheimer's DiseaseNCT01852110Merck Sharp & Dohme LLC240
已完成
2 期
MK3207 for Treatment of Acute Migraines (3207-005)MigraineNCT00712725Merck Sharp & Dohme LLC676
已完成
1 期
A Study to Test Once-Weekly Doses of Odanacatib (MK0822) on Healthy Adult Females (0822-005)(COMPLETED)OsteoporosisNCT00770159Merck Sharp & Dohme LLC78